|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||0.9980 - 1.0000|
|52-week range||0.9980 - 1.0000|
|Beta (5Y monthly)||1.46|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Ginkgo is teaming up with Synlogic to launch a new gout drug, moving shares of both stocks higher.
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 49.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...